- Home
- SGMT vs ZURA Comparison
SGMT vs ZURA Comparison
Compare SGMT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- ZURA
- Stock Information
- Founded
- SGMT 2006
- ZURA 2022
- Country
- SGMT United States
- ZURA United States
- Employees
- SGMT N/A
- ZURA N/A
- Industry
- SGMT
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGMT
- ZURA Health Care
- Exchange
- SGMT Nasdaq
- ZURA Nasdaq
- Market Cap
- SGMT 71.2M
- ZURA 76.6M
- IPO Year
- SGMT 2023
- ZURA N/A
- Fundamental
- Price
- SGMT $3.55
- ZURA $1.01
- Analyst Decision
- SGMT Strong Buy
- ZURA Buy
- Analyst Count
- SGMT 6
- ZURA 7
- Target Price
- SGMT $25.67
- ZURA $14.33
- AVG Volume (30 Days)
- SGMT 392.3K
- ZURA 520.6K
- Earning Date
- SGMT 05-08-2025
- ZURA 05-08-2025
- Dividend Yield
- SGMT N/A
- ZURA N/A
- EPS Growth
- SGMT N/A
- ZURA N/A
- EPS
- SGMT N/A
- ZURA N/A
- Revenue
- SGMT N/A
- ZURA N/A
- Revenue This Year
- SGMT N/A
- ZURA N/A
- Revenue Next Year
- SGMT N/A
- ZURA N/A
- P/E Ratio
- SGMT N/A
- ZURA N/A
- Revenue Growth
- SGMT N/A
- ZURA N/A
- 52 Week Low
- SGMT $1.73
- ZURA $0.97
- 52 Week High
- SGMT $7.38
- ZURA $5.56
- Technical
- Relative Strength Index (RSI)
- SGMT 57.81
- ZURA 35.69
- Support Level
- SGMT $3.18
- ZURA $0.99
- Resistance Level
- SGMT $3.85
- ZURA $1.06
- Average True Range (ATR)
- SGMT 0.27
- ZURA 0.08
- MACD
- SGMT 0.01
- ZURA -0.01
- Stochastic Oscillator
- SGMT 61.04
- ZURA 7.17
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.